Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/1/2025

CREST Syndrome Diagnostic Approach

Initial Evaluation

  • A complete blood count should be performed to assess for anemia and inflammatory markers in patients with suspected CREST syndrome, as part of the initial screening process 1
  • Doppler echocardiography is essential to screen for pulmonary arterial hypertension (PAH), assess right ventricular function, and evaluate for left-sided heart disease in patients with limited scleroderma 1
  • Pulmonary function tests with DLCO should be conducted, as a marked isolated decrease in DLCO is highly predictive of PAH development, with serial measurements showing a linear decline years before PAH diagnosis 1
  • High-resolution chest CT should be used to evaluate for interstitial lung disease, though it is less common in limited versus diffuse scleroderma 1
  • The American College of Chest Physicians recommends that patients with limited scleroderma and isolated DLCO <55% predicted undergo annual echocardiographic screening, due to the 35% risk of developing PAH 1
  • The American College of Cardiology suggests that chest radiograph is used as a baseline assessment for pulmonary involvement in patients with CREST syndrome 1
  • CT chest without contrast is indicated if DLCO is reduced or there is clinical suspicion for ILD, according to the American Thoracic Society 1
  • Cardiac MRI is recommended if echocardiography suggests PAH or right ventricular dysfunction, as stated by the American Heart Association 1
  • Patients with anticentromere antibodies and anti-U3-RNP or anti-nucleolar antibodies are at higher risk for PAH, and should be closely monitored, as advised by the European Respiratory Society 1
  • Disease onset after menopause is associated with isolated PAH development, and patients should be closely monitored, according to the American College of Rheumatology 1
  • A DLCO <55% predicted is associated with a 35% risk of developing PAH, and patients should undergo regular monitoring, as recommended by the European Society of Cardiology 1
  • Referral to pulmonology is recommended if DLCO <60% predicted or echocardiographic evidence of PAH is present, as stated by the American Thoracic Society 1
  • Referral to cardiology is recommended for elevated pulmonary artery pressures on echocardiography (sPAP >30 mmHg), as advised by the American Heart Association 1